Once again I seem to have underestimated how Wall Street's love of a good story can overpower and outweigh the likely long-term economic returns from that story. In the case of Edwards Lifesciences (NYSE:EW), I have never doubted that transcatheter aortic valve replacement (TAVR) (also called "... valve implantation" or TAVI) was going to be successful, nor that Edwards' Sapien would be a major player.
What I doubted was whether Wall Street would keep pumping up the valuation it was willing to pay. With Edwards being one of the relatively few double-digit organic growth stories in med-tech, the stock is up about 30% since my last skeptical piece - not all that much better than other med-tech names...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|